A study published in Gastroenterology demonstrated that the TissueCypher® Barrett’s Esophagus test, developed by Castle Biosciences, Inc., surpassed the standard of care pathology review in predicting the progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus (BE) initially diagnosed with low-grade dysplasia (LGD). The study involved 154 BE patients and compared the test’s performance against a panel of expert and community-based pathologists. TissueCypher showed higher sensitivity in detecting patients progressing to HGD/EAC. The test uses Artificial Intelligence to provide objective information about a patient’s risk of progressing to esophageal cancer.
- Performance Metrics: The TissueCypher test demonstrated a sensitivity of 71% in detecting patients who progressed to HGD/EAC, outperforming the average sensitivity of 63% achieved by the panel of pathologists.
- Early Detection: The TissueCypher test, when combined with pathology review, identified 80.4% of patients who progressed. This suggests that the test can enhance early detection when used alongside traditional pathology.
- Addressing Variability: The study highlighted the significant variability in pathology diagnoses of Barrett’s esophagus. TissueCypher offers an objective solution to this variability, enabling more informed patient management decisions.